U ntil recently, no treatments were available to help slow the progression of metabolic dysfunction–associated steatohepatitis (MASH), a severe form of fatty liver disease. But in March 2024, a ...
Please provide your email address to receive an email when new articles are posted on . Of 145,410 adults who began a GLP-1 drug, 76 developed thyroid cancer over a mean 3.9 years of follow-up. Risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results